Loading
A phase 3 trial of Cediranib in Glioma & glioblastoma, run by AstraZeneca, completed.
Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma is a phase 3 interventional study registered as NCT00777153 by AstraZeneca, with 423 participants recorded, started 2008-10 and reaching its primary completion in 2010-04. Interventions recorded: Cediranib, Cediranib, Lomustine Chemotherapy, Placebo Cediranib. Conditions recorded: Recurrent Glioblastoma.
Linked to the drug Cediranib because the registry names it among its interventions and Glioma & glioblastoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
423 enrolled.
IQR 80 to 128; Figures from the ClinicalTrials.gov results section (first posted 2012-12-21), not from a publication · IQR 83 to 201 · IQR 42 to 168
SourceIQR 4.1 to 14.5; Figures from the ClinicalTrials.gov results section (first posted 2012-12-21), not from a publication · IQR 6.2 to 14.5 · IQR 4.9 to NA
SourceShares AstraZeneca, Glioma & glioblastoma and the tag pipeline.
Shares Cediranib, AstraZeneca and the tag pipeline.
Shares Cediranib and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares Glioma & glioblastoma and the tag pipeline.
Shares AstraZeneca and the tag pipeline.